Brokers Set Expectations for COCP Q3 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Investment analysts at Zacks Small Cap issued their Q3 2025 EPS estimates for Cocrystal Pharma in a report issued on Tuesday, April 1st. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.45) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s Q4 2025 earnings at ($0.36) EPS and FY2027 earnings at ($1.20) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Cocrystal Pharma in a research note on Wednesday, January 22nd.

Cocrystal Pharma Stock Performance

Shares of COCP stock opened at $1.42 on Wednesday. Cocrystal Pharma has a twelve month low of $1.35 and a twelve month high of $3.26. The stock has a fifty day simple moving average of $1.79 and a two-hundred day simple moving average of $1.93. The stock has a market capitalization of $14.45 million, a price-to-earnings ratio of -0.77 and a beta of 2.35.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.23.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.